From November 1981 to February 1983, 64 patients with advanced head and neck squamous carcinoma were randomly treated with either high-dise (120 mg/m2) or low-dose (60 mg/m2) cisplatin. Of the 62 eligible patients, 59 were evaluable: the response rate observed in patients receiving high-dose and low-dose cisplatin was 16.1% and 17.8%, respectively. Survival was superimposable in the two treatment arms. No evidence of dose dependency of cisplatin activity in advanced head and neck squamous carcinoma was noted in this randomized trial.
|Number of pages||4|
|Journal||Journal of Clinical Oncology|
|Publication status||Published - 1985|
ASJC Scopus subject areas
- Cancer Research